Enhancing Scientific Leadership and Strategic Communication for Steroid Reduction Therapy
Introduction
Our client’s therapy for a rare neurological disorder has gained attention as KOLs advocate for reducing steroid use in favor of more aggressive treatments. While US guidelines remain static, global guidelines are shifting due to steroids’ long-term risks. Despite having unique data supporting reduced steroid use, adoption of this new approach is slow.
The Problem
Our client was looking to drive this shifting treatment paradigm in steroid/concomitant drug reduction and position their therapy as the ideal choice for this indication. Initial plans were solely based on scientific communication. Our client needed help creating this shift globally, finding out where to focus efforts, and what to communicate around.
Our Solution
Our multifaceted strategy allowed the Client to leverage expert insights while addressing key challenges in their therapeutic area:
- Conducted a robust gap analysis to identify significant gaps related to steroid use, providing the Client with critical insights into existing data and areas for further exploration
- Established a global scientific advisory committee comprised of key opinion leaders (KOLs) who refined data generation and communication strategies
- This committee provided ongoing input over 12 months, enabling the Client to effectively drive steroid reduction initiatives
- Identified the opportunity for a KOL-led case review manuscript focused on concomitant drug use and treatment management
Value Delivered
- Supported the shifting treatment paradigm and informed the Client’s Phase 4 study
- Enabled real-world evidence (RWE), post-hoc, and sub-analyses to enhance the scientific narrative
- Strengthened the scientific story and market position through strategic working groups
- Enhanced engagement with healthcare providers and payers, demonstrating the treatment’s value
